litlas
Log inCreate account

Caicun Zhou

Active 1999–2025

289
Papers
51,037
Citations
99
h-index
269
i10-index

Citations

Citations per year for Caicun Zhou1971: 1 citations1993: 1 citations2000: 1 citations2001: 1 citations2003: 1 citations2007: 1 citations2008: 1 citations2009: 1 citations2010: 3 citations2011: 28 citations2012: 75 citations2013: 158 citations2014: 166 citations2015: 285 citations2016: 356 citations2017: 349 citations2018: 419 citations2019: 1,799 citations2020: 2,097 citations2021: 2,591 citations2022: 2,319 citations2023: 1,846 citations2024: 3,303 citations2025: 1,792 citations2026: 48 citations1972–1992: no citations, so these years are not shown1994–1999: no citations, so these years are not shown2002: no citations, so this year is not shown2004–2006: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 4,864 citing papers, 25.6% of this breakdownUnited States: 3,622 citing papers, 19.1% of this breakdownJapan: 915 citing papers, 4.8% of this breakdownItaly: 882 citing papers, 4.6% of this breakdownUnited Kingdom: 745 citing papers, 3.9% of this breakdownGermany: 648 citing papers, 3.4% of this breakdownFrance: 625 citing papers, 3.3% of this breakdownSpain: 603 citing papers, 3.2% of this breakdownSouth Korea: 592 citing papers, 3.1% of this breakdownCanada: 435 citing papers, 2.3% of this breakdownNetherlands: 416 citing papers, 2.2% of this breakdownTaiwan: 387 citing papers, 2% of this breakdown
0%25.6%Other 22.5%

Institutions

Fields

  • Medicine70.3%
  • Biochemistry, Genetics and Molecular Biology19.7%
  • Immunology and Microbiology6.1%
  • Engineering1.1%
  • Chemistry0.5%
  • Computer Science0.5%
  • Other1.8%

Topics

  • Lung Cancer Treatments and Mutations14%
  • Cancer Immunotherapy and Biomarkers9.6%
  • Lung Cancer Research Studies8.1%
  • Lung Cancer Diagnosis and Treatment5%
  • Cancer Genomics and Diagnostics3.8%
  • Immunotherapy and Immune Responses2.2%
  • Other57.3%

Coauthors

All papers

Open in search
  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

    Authors: Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam - New England Journal of Medicine 2017 cited by 5,269

  2. Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

    Authors: Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria - New England Journal of Medicine 2019 cited by 2,816

  3. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Authors: Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz and 146 more - The Lancet 2019 cited by 2,199

  4. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

    Authors: Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, А. Л. Акопов, Alex Martínez‐Martí, Hirotsugu Kenmotsu, Yuh‐Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark L. McCleland, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee - The Lancet 2021 cited by 1,479

  5. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer

    Authors: Fengying Wu, Jue Fan, Yayi He, Anwen Xiong, Jia Yu, Yixin Li, Yan Zhang, Wencheng Zhao, Fei Zhou, Wei Li, Jie Zhang, Xiaosheng Zhang, Meng Qiao, Guanghui Gao, Shanhao Chen, Xiaoxia Chen, Xuefei Li, Likun Hou, Chunyan Wu, Chunxia Su, Shengxiang Ren, Margarete Odenthal, Reinhard Buettner, Nan Fang, Caicun Zhou - Nature Communications 2021 cited by 803

  6. cGAS-STING, an important pathway in cancer immunotherapy

    Authors: Minlin Jiang, Peixin Chen, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Lingyun Ye, Yayi He, Caicun Zhou - Journal of Hematology & Oncology 2020 cited by 653

  7. Non‐small cell lung cancer in China

    Authors: Peixin Chen, Yunhuan Liu, Yaokai Wen, Caicun Zhou - Cancer Communications 2022 cited by 639

  8. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    Authors: Caicun Zhou, Kejing Tang, Byoung Chul Cho, Baogang Liu, Luis Paz‐Ares, Susanna Y. Cheng, Satoru Kitazono, Muthukkumaran Thiagarajan, Jonathan W. Goldman, Joshua K. Sabari, Rachel E. Sanborn, Aaron S. Mansfield, Jen‐Yu Hung, Michael Boyer, Sanjay Popat, Josiane Mourão Dias, Enriqueta Felip, Margarita Majem, Mahmut Gümüş, Sang‐We Kim, Akira Ono, John Xie, Archan Bhattacharya, Trishala Agrawal, S. Martin Shreeve, Roland E. Knoblauch, Keunchil Park, Nicolas Girard - New England Journal of Medicine 2023 cited by 347

  9. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Ben Zhang, Wei Shi, Xiaojing Zhang, Ying Cheng, Ying Cheng, Ying Cheng, Ying Cheng, Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Huiqing Yu, Jian Zhao, Gang Wu, Dingzhi Huang, Chengshui Chen, Cuimin Ding, Baihong Zhang, Xiuwen Wang, Hui Luo, Baolan Li, Shucai Zhang, Hong Lu, Meiqi Shi, Xi Chen, Yubiao Guo, Hailong Liu, Jiwei Liu, Hongjun Gao, Sheng Hu, Qunying Hong, Qi Li, Ben Zhang, Wei Shi, Xiaojing Zhang - The Lancet Oncology 2022 cited by 395

  10. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

    Authors: Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You - The Lancet Oncology 2011 cited by 4,102

  11. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Authors: Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, Manuel Cobo, Eun Kyung Cho, Alessandro Bertolini, Sabine Bohnet, Caicun Zhou, Ki Hyeong Lee, Naoyuki Nogami, Isamu Okamoto, Natasha B. Leighl, Rachel Hodge, Astrid McKeown, Andy Brown, Yuri Rukazenkov, Suresh S. Ramalingam, Johan Vansteenkiste - Journal of Clinical Oncology 2018 cited by 789

  12. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

    Authors: Shengxiang Ren, Jianhua Chen, Xingxiang Xu, Tao Jiang, Ying Cheng, Gongyan Chen, Yueyin Pan, Yong Fang, Qiming Wang, Yunchao Huang, Wenxiu Yao, Rui Wang, Xingya Li, Wei Zhang, Yanjun Zhang, Sheng Hu, Renhua Guo, Jianhua Shi, Zhiwu Wang, Peiguo Cao, Donglin Wang, Jian Fang, Hui Luo, Yi Geng, Chunyan Xing, Dongqing Lv, Yiping Zhang, Junyan Yu, Shundong Cang, Zeyu Yang, Wei Shi, Jianjun Zou, Caicun Zhou - Journal of Thoracic Oncology 2021 cited by 313

  13. Role of IL-2 in cancer immunotherapy

    Authors: Tao Jiang, Caicun Zhou, Shengxiang Ren - OncoImmunology 2016 cited by 539

  14. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

    Authors: Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Eric Vallières, Alex Martínez‐Martí, Achim Rittmeyer, Antonio Chella, Martin Reck, O. Goloborodko, Meijuan Huang, R. Belleli, Virginia McNally, Minu K. Srivastava, Elizabeth Bennett, B.J. Gitlitz, H. Wakelee - Annals of Oncology 2023 cited by 251

  15. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

    Authors: Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater - The Lancet Oncology 2014 cited by 1,977

  16. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

    Authors: Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, Liping Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Tao Zhang, Wei Shi, Jianjun Zou - The Lancet Respiratory Medicine 2020 cited by 505

  17. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

    Authors: Minlin Jiang, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou - Acta Pharmaceutica Sinica B 2021 cited by 321

  18. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

    Authors: Caicun Zhou, Benjamin Solomon, Herbert H. Loong, Keunchil Park, M. Pérol, Edurne Arriola, Silvia Novello, Baohui Han, Jianying Zhou, Andrea Ardizzoni, M. Perez Mak, Fernando C. Santini, Yasir Y. Elamin, Alexander Drilon, Jürgen Wolf, Nalin Payakachat, Minji K. Uh, Deborah Rajakumar, Hongmei Han, Tarun Puri, Victoria Soldatenkova, Aimee Bence Lin, Boris K. Lin, Kōichi Goto - New England Journal of Medicine 2023 cited by 213

  19. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

    Authors: Caicun Zhou, Caicun Zhou, Lin Wu, Yun Fan, Zhehai Wang, Lianke Liu, Gongyan Chen, Li Zhang, Dingzhi Huang, Shundong Cang, Zhixiong Yang, Jianying Zhou, Chengzhi Zhou, Chengzhi Zhou, Baolan Li, Juan Li, Min Fan, Jiuwei Cui, Yuping Li, Hui Zhao, Jian Fang, Jianxin Xue, Chengping Hu, Ping Sun, Yingying Du, Hui Zhou, Shuyan Wang, Wen Zhang - Journal of Thoracic Oncology 2021 cited by 317

  20. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

    Authors: Zhe Yang, Nong Yang, Qiuxiang Ou, Yi Xiang, Tao Jiang, Xue Wu, Hua Bao, Xiaoling Tong, Xiaonan Wang, Yang Shao, Yunpeng Liu, Yan Wang, Caicun Zhou - Clinical Cancer Research 2018 cited by 544

  21. PD-L1 Expression in Lung Cancer

    Authors: Hui Yu, Theresa A. Boyle, Caicun Zhou, David L. Rimm, Fred R. Hirsch - Journal of Thoracic Oncology 2016 cited by 492

  22. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

    Authors: James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Mok, Martin Schüler, Nobuyuki Yamamoto, Chong‐Jen Yu, Sai‐Hong Ignatius Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi‐Long Wu - The Lancet Oncology 2015 cited by 982

  23. The cutting-edge progress of immune-checkpoint blockade in lung cancer

    Authors: Fei Zhou, Meng Qiao, Caicun Zhou - Cellular and Molecular Immunology 2020 cited by 240

  24. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

    Authors: Caicun Zhou, Ziping Wang, Yuping Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Jianhua Chang, Jianhua Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lu, Hong Shen, Jingru Wang, Peiqi Li, Mengmeng Qin, Dongmei Lu, Jason Yang - The Lancet Oncology 2022 cited by 224